Verastem, Inc. — Regulatory Filings 2021

Jun 24, 2021

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 24, 2021

Verastem, Inc.

(Exact Name of Registrant as Specified in Charter)

​	​	​	​	​
Delaware	​	001-35403	​	27-3269467
(State or Other Jurisdiction of Incorporation)	​	(Commission File Number)	​	(IRS Employer Identification No.) ​

​	​	​
117 Kendrick Street , Suite 500 , Needham , MA	​	02494
(Address of Principal Executive Offices)	​	(Zip Code) ​

Registrant’s telephone number, including area code: ( 781 ) 292-4200

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

​	​	​	​	​
Title of each class	​	Trading Symbol(s)	​	Name of each exchange on which registered
Common stock, $0.0001 par value per share	​	VSTM	​	The Nasdaq Global Market ​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 24, 2021, the board of directors (the “Board”) of Verastem, Inc. (the “Company”) unanimously voted to elect Ms. Lesley Solomon and Dr. Paul Bunn as Class III directors of the Company and for Ms. Solomon to serve on the audit and nominating and corporate governance committees of the Board and for Dr. Bunn to serve on the research and development committee of the Board, effective immediately. In connection with their appointments as directors, Ms. Solomon and Dr. Bunn each received a stock option grant of 73,356 shares of the Company’s common stock. Ms. Solomon and Dr. Bunn will each be eligible to receive certain annual cash retainer fees and an annual stock option grant under the Company’s director compensation policy. Ms. Solomon and Dr. Bunn each also entered into customary indemnification agreements with the Company.

A press release announcing Ms. Solomon’s and Dr. Bunn’s appointments and other matters is filed as Exhibit 99.1 hereto.

Item 9.01. Financial Statements and Exhibits

​ ​ — Exhibit No.		Description
99.1		Press Release issued by Verastem, Inc. on June 24, 2021
104	​	Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​	​	​
​	VERASTEM, INC.
​	​	​
Dated: June 24, 2021	By:	/s/ Brian M. Stuglik
​	​	Brian M. Stuglik
​	​	Chief Executive Officer